• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Electromed Inc.

    11/21/24 4:09:11 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ELMD alert in real time by email
    SC 13D/A 1 skarvan241208_13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13D/A

    (Amendment No. 3)

    Under the Securities Exchange Act of 1934

     

    ELECTROMED, INC.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share
    (Title of Class of Securities)

     

    285409108
    (CUSIP Number)

     

    Kathleen S. Skarvan

    500 Sixth Avenue NW
    New Prague, MN 56071

    952-758-9299

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    November 19, 2024
    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 285409108
     
      1. Names of reporting persons
        Kathleen S. Skarvan
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ☐
        (b)  ☐
     
      3. SEC Use Only
     
      4.

    Source of Funds (See Instructions)

    SC/PF

     
      5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

    ☐

     
      6.

    Citizenship or Place of Organization

    USA

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

       
    7.

    Sole Voting Power

    303,094

     
    8.

    Shared Voting Power

    28,989

     
    9.

    Sole Dispositive Power

    303,094

     
    10.

    Shared Dispositive Power

    28,989

     
      11.

    Aggregate Amount Beneficially Owned by Each reporting person

    332,083

     
      12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ☐
     
      13.

    Percent of Class Represented by Amount in Row (11) 

    3.93%(1)

     
      14.

    Type of reporting person (See Instructions)

    IN

     

     

      (1) The percentage is based upon 8,458,005 shares of common stock outstanding as of November 7, 2024 as reported by the Issuer in its latest Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 12, 2024.

     

     

     

    EXPLANATORY NOTE

     

    This Amendment No. 3 to Schedule 13D (“Amendment No. 3”) is being filed solely to consistently state Kathleen S. Skarvan’s (the “Reporting Person”) positions with Electromed, Inc. (the “Issuer”). This Amendment No. 3 amends and supplements the initial statement on Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) by the Reporting Person on July 1, 2022, as amended by Amendment No. 1 to Schedule 13D filed with the SEC on July 12, 2022, and Amendment No. 2 to Schedule 13D filed with the SEC on February 14, 2023 (as amended, this “Schedule 13D”).

     

    Item 1. Security and Issuer
       
      This Schedule 13D relates to the Common Stock, par value $0.001 per share (“Common Stock”), of the Issuer, 500 Sixth Avenue NW, New Prague, MN 56071.
     
    Item 2. Identity and Background
       
     

    (a) The person filing this Schedule 13D is Kathleen S. Skarvan

     

    (b) Business address: 500 Sixth Avenue NW, New Prague, MN 56071

     

    (c) Principal occupation: Retired

     

    (d) Criminal proceedings: The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e) The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which the Reporting Person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f) The Reporting person is a citizen of the United States of America.

     
    Item 3. Source and Amount of Funds or Other Consideration
       
      Not applicable.

     

    Item 4. Purpose of Transaction
       
     

    Item 4 is hereby amended and supplemented as follows:

     

    On November 18, 2024, the Reporting Person sold 42,453 shares of Common Stock held directly with an average price of $28.1641. On November 19, 2024 the Reporting Person sold 50,602 shares of Common Stock held directly and 56,945 shares of Common Stock held indirectly at average prices of $27.9221 and $27.9706, respectively. These sales of shares reported are part of the Reporting Person’s disciplined, long-term strategy to support personal initiatives for portfolio diversification and individual financial and retirement planning. This approach is not indicative of any current change in the Reporting Person’s outlook on the Issuer’s potential. As a result of these transactions, the Reporting Person’s ownership in the Issuer fell below the 5% threshold and the Reporting Person will not file future amendments unless required to do so. 

       

     

     

     

    Item 5. Interest in Securities of the Issuer
       
     

    (a)    The Reporting Person is deemed to beneficially own an aggregate of 332,083 shares of Common Stock, as follows (i) 52,394 shares of Common Stock and (ii) options to purchase 250,700 shares of Common Stock under the Issuer’s equity incentive plans, which represents beneficial ownership of approximately 3.93% of the Common Stock. The percentage is based upon 8,458,005 shares of common stock outstanding as of November 7, 2024, as reported by the Issuer in its latest Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 12, 2024.

     

    Does not include 9,600 shares underlying options to purchase Common Stock, which were issued to the Reporting Person under the Issuer’s 2017 Omnibus Incentive Plan, as they are not scheduled to vest within 60 days of the date of this Schedule 13D.

     

    (b)    The Reporting Person has sole power to vote and dispose of 303,094 shares and all of the shares underlying options, as identified in Item 5(a).

     

    The Reporting Person has shared power to vote and dispose of 28,989 shares held by a trust, of which the Reporting Person is a co-trustee and beneficiary.

     

    (c)    No transactions in the securities of the Issuer were effected by the Reporting Person during the past sixty days.

     

    (d)    Except as described herein with respect to indirect holdings by the Reporting Person, the Reporting Person does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of any of the securities described herein.

     

    (e)    On November 19, 2024, the Reporting Person ceased being a holder of 5% or more of the outstanding shares of the Issuer’s Common Stock.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
       
     

    The information contained in Items 2, 3, 4 and 5 of this Schedule 13D is incorporated by reference herein.

     

    To the best knowledge of the Reporting Person, except as set forth herein in this Schedule 13D, there are no other contracts, arrangements, understandings or relationships (legal or otherwise), including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies, between the Reporting Person, and any other person, with respect to any securities of the Issuer, including any securities pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities other than standard default and similar provisions contained in loan agreements.

     

    Item 7. Material to be Filed as Exhibits
       
      None.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 21, 2024 /s/ Kathleen S. Skarvan
      Kathleen S. Skarvan

     

     

    Get the next $ELMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELMD

    DatePrice TargetRatingAnalyst
    7/22/2025$29.00Buy
    Roth Capital
    2/20/2025$38.00Buy
    B. Riley Securities
    More analyst ratings

    $ELMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Electromed, Inc. to Report Q4 Fiscal 2025 Financial Results on August 26, 2025

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2025 fourth quarter ended June 30, 2025, on August 26, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q4 FY 202

    8/12/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. to Participate in the Canaccord Genuity 45th Annual Growth Conference

    Management will present Tuesday, August 12 at 12:30 pm ET Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that Company management will participate in the Canaccord Genuity 45th Annual Growth Conference, which will be held August 12-14, 2025 in Boston, MA. Electromed President and Chief Executive Officer Jim Cunniff, and Chief Financial Officer Brad Nagel will present on Tuesday, August 12 at 12:30 pm ET. Interested parties may access a live webcast of the presentation using the following link: Electromed CG Presentation. The link will also be posted on the Electromed Investor Relations website under Events

    7/29/25 8:30:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. to Join Russell 2000® and Russell 3000® Indexes

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Electromed is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products," said Jim Cunniff, Electromed's President and Chief Executive Off

    5/27/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cunniff James L. bought $137,250 worth of shares (9,000 units at $15.25), increasing direct ownership by 900% to 10,000 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    3/5/24 4:49:02 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Summers Andrew bought $302,368 worth of shares (28,797 units at $10.50) (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/18/23 4:44:26 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cunniff James L. bought $10,560 worth of shares (1,000 units at $10.56) (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    11/22/23 4:01:43 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Electromed with a new price target

    Roth Capital initiated coverage of Electromed with a rating of Buy and set a new price target of $29.00

    7/22/25 7:52:34 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    B. Riley Securities initiated coverage on Electromed with a new price target

    B. Riley Securities initiated coverage of Electromed with a rating of Buy and set a new price target of $38.00

    2/20/25 7:01:40 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Electromed Inc.

    SCHEDULE 13G - Electromed, Inc. (0001488917) (Subject)

    7/29/25 1:04:56 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SD filed by Electromed Inc.

    SD - Electromed, Inc. (0001488917) (Filer)

    5/29/25 5:16:40 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Electromed Inc.

    10-Q - Electromed, Inc. (0001488917) (Filer)

    5/13/25 4:11:08 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Summers Andrew sold $3,120,226 worth of shares (111,475 units at $27.99) (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    2/24/25 9:38:48 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Skarvan Kathleen exercised 40,000 shares at a strike of $1.80, covered exercise/tax liability with 15,178 shares and sold $2,334,281 worth of shares (76,583 units at $30.48), decreasing direct ownership by 41% to 32,622 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    2/19/25 6:00:23 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CEO and President Cunniff James L. converted options into 87,500 shares and covered exercise/tax liability with 34,432 shares, increasing direct ownership by 67% to 132,042 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    1/3/25 4:36:27 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Electromed Inc.

    SC 13D/A - Electromed, Inc. (0001488917) (Subject)

    11/21/24 4:09:11 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Electromed Inc.

    SC 13G/A - Electromed, Inc. (0001488917) (Subject)

    11/13/24 5:42:25 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Electromed Inc.

    SC 13G/A - Electromed, Inc. (0001488917) (Subject)

    11/12/24 4:09:16 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Leadership Updates

    Live Leadership Updates

    View All

    Electromed, Inc. to Join Russell 2000® and Russell 3000® Indexes

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Electromed is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products," said Jim Cunniff, Electromed's President and Chief Executive Off

    5/27/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc., Appoints Peter Horwich, Vice President, Marketing

    Key hire will drive the Company's market development and therapy adoption initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Peter Horwich as Vice President, Marketing. Mr. Horwich, an accomplished marketing veteran, brings over 20 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Horwich directed Global Strategic Marketing for Respiratory Therapies at Abiomed (now J&J MedTech), a Medical Device manufacturer of extracorporeal membrane oxygenation (ECMO) lung recovery systems, where he was responsible for global marketing

    10/28/24 8:30:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed Names Jim Cunniff as President and Chief Executive Officer

    Healthcare Executive Brings More Than 30 Years of Executive Experience and Commercial Success to Electromed Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023. Mr. Cunniff will also join Electromed's Board of Directors. "We are pleased to announce the appointment of Jim Cunniff as president and CEO," said Lee Jones, Chair of the Board. "Jim is a proven executive with deep experience driving growth and profitability through excellence in products and services that benefit patients and support care teams. "As Kathle

    6/5/23 8:15:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Financials

    Live finance-specific insights

    View All

    Electromed, Inc. to Report Q4 Fiscal 2025 Financial Results on August 26, 2025

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2025 fourth quarter ended June 30, 2025, on August 26, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q4 FY 202

    8/12/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. Schedules its Third Quarter Fiscal 2025 Financial Results Conference Call for May 13, 2025 at 5:00 p.m. ET

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2025 third quarter ended March 31, 2025, on May 13, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q3 Fiscal 2025

    4/29/25 8:30:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. Announces Record Financial Performance in Fiscal 2025 Second Quarter

    Company maintained strong momentum to deliver another quarter of record revenue and earnings, while continuing to invest in multiple strategic growth initiatives Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three and six months ended December 31, 2024 ("Q2 FY 2025"). Q2 FY 2025 Company Highlights Net revenue increased 18.7% to a record $16.3 million in Q2 FY 2025, from $13.7 million in the second quarter of the prior fiscal year. Operating income increased to a record $2.5 million, 15.6% of net revenues and a year-over-year increase of 12.3%. Net income was $2.0 mill

    2/11/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care